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Abstract
Background: Dysregulated WNT signaling dominates adrenocortical malignancies. This study investigates whether
silencing of the WNT negative regulator DKK3 (Dickkopf-related protein 3), an implicated adrenocortical differentiation
marker and an established tumor suppressor in multiple cancers, allows dedifferentiation of the adrenal cortex.
Methods: We analyzed the expression and regulation of DKK3 in human adrenocortical carcinoma (ACC) by qRT-PCR,
immunofluorescence, promoter methylation assay, and copy number analysis. We also conducted functional studies on
ACC cell lines, NCI-H295R and SW-13, using siRNAs and enforced DKK3 expression to test DKK3’s role in blocking
dedifferentiation of adrenal cortex.
Results: While robust expression was observed in normal adrenal cortex, DKK3 was down-regulated in the majority
(>75%) of adrenocortical carcinomas (ACC) tested. Both genetic (gene copy loss) and epigenetic (promoter methylation)
events were found to play significant roles in DKK3 down-regulation in ACCs. While NCI-H295R cells harboring β-catenin
activating mutations failed to respond to DKK3 silencing, SW-13 cells showed increased motility and reduced clonal
growth. Conversely, exogenously added DKK3 also increased motility of SW-13 cells without influencing their growth.
Enforced over-expression of DKK3 in SW-13 cells resulted in slower cell growth by an extension of G1 phase, promoted
survival of microcolonies, and resulted in significant impairment of migratory and invasive behaviors, largely attributable
to modified cell adhesions and adhesion kinetics. DKK3-over-expressing cells also showed increased expression of
Forkhead Box Protein O1 (FOXO1) transcription factor, RNAi silencing of which partially restored the migratory proficiency
of cells without interfering with their viability.
Conclusions: DKK3 suppression observed in ACCs and the effects of manipulation of DKK3 expression in ACC cell lines
suggest a FOXO1-mediated differentiation-promoting role for DKK3 in the adrenal cortex, silencing of which may allow
adrenocortical dedifferentiation and malignancy.
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Background
Adrenocortical carcinoma (ACC) is a rare (0.5–2 cases
per million/year) endocrine malignancy that carries a
poor prognosis at diagnosis due to its propensity to
metastasize before detection. Even with aggressive surgi-
cal and oncologic therapy, the 5-year survival rate is an
abysmal 16–38% [1–4]. A major reason for the lack of
an effective targeted treatment strategy for ACCs is an
inadequate understanding of the molecular pathogenesis
of the disease [3, 4].
Genetic and epigenetic dysregulations of the WNT, p53,
and IGF2 pathways appear to dominate various cancer-
driving anomalies in the majority of ACCs [5–7]. Recent
findings from comprehensive genetic analyses of ACCs
confirmed a signature role for WNT dysregulation in the
origin and/or progression of ACCs [4, 6, 8, 9]. Physiologic-
ally, both canonical and non-canonical WNT signaling
pathways play global and zone-specific roles in the devel-
opment, differentiation, and homeostasis of the adrenal
gland [10, 11]. In particular, endocrine homeostasis of the
adrenal glomerulosa and fasciculata zones is largely
controlled by WNT-differentiation signaling mediated by
the Wnt4-Fz1/2-Dvl3-β-Catenin-SF1 axis [12–16]. Regula-
tory components of this proposed adrenal cortex-specific
Wnt4 axis include the secretory factors, frizzled-related
protein 1 (SFRP1) and the putative tumor suppressor,
DKK3 [14, 17, 18]. Aberrant WNT signaling has been
well-established in the origin of many tumor types and is
strongly associated with stabilization of β-catenin in the
cytoplasm and/or in the nucleus and constitutive activa-
tion of WNT target genes [19, 20]. Similar stabilization
and nuclear accumulation of β-catenin is seen in benign ad-
renocortical adenomas (ACAs) and frequently in malignant
ACCs [10, 21]. However, only 10% of ACCs with constitu-
tively active β-catenin carry mutations in the β-catenin gene
(CTNNB1), suggesting alternate mechanisms of aberrant
WNT activation, including dysregulation of WNT inhibi-
tors such as Wif-1 [22]. Other WNT regulatory mutations
found in ACCs include PRKAR1A [23] and recently identi-
fied KREMEN1 and ZNRF3 gene deletions [8, 24].
Although implicated in zonal differentiation and hor-
mone biosynthesis [14, 25], a definitive role for the ubiqui-
tous WNT inhibitor DKK3 in promoting functional
differentiation and/or blocking tumor dedifferentiation of
the adrenal cortex has yet to be clarified. The inhibitory
role of DKK3 in WNT signaling is context-dependent and
appears to be influenced by a repertoire of cell surface re-
ceptors and co-expressed ligands [26]. DKK3, a 38 kDa se-
creted glycoprotein with an N-terminal signal peptide, is
also implicated in eliciting distinct intracellular roles in
addition to its secretory functions [27]. Reduced DKK3 ex-
pression is observed in a variety of solid tumors, and re-
expression studies in multiple cancer cell types mostly re-
sulted in cell cycle arrest and/or apoptosis, strongly
suggesting a global tumor suppressor role for this WNT
regulator (reviewed in [26]). Furthermore, ectopic
expression of DKK3 in a variety of cancer cell types stifled
aggressive malignant behavior, reversed epithelial-
mesenchymal transition (EMT), and impaired cell motility,
pointing towards a comprehensive dedifferentiation-
blocking role for DKK3 [28, 29]. This study investigates a
potential tumor suppressor role for the implicated adrenal




Written informed consent was obtained from patients
prior to surgical resection of adrenal tissue according to
protocols approved by Institutional Review Boards at (a)
Yale University, New Haven, CT, USA, (b) Heinrich Heine
University Düsseldorf, Düsseldorf, Germany, and (c) Karo-
linska Institutet, Stockholm, Sweden. Tissue samples were
flash-frozen (FF) in liquid nitrogen and stored at −80 °C
until processed for study. Specimens displaying unequivo-
cal histopathological characteristics of ACCs (n = 38) and
histologically normal adrenal tissue (n = 14) samples ex-
cised with ACAs were selected for study. Consecutive un-
stained/hematoxylin & eosin (H&E) stained 5 μM sections
of formalin-fixed, paraffin-embedded (FFPE) tissue sam-
ples underwent immunohistochemistry analyses. All sam-
ples were histopathologically confirmed by experienced
endocrine pathologists before processing.
DNA, RNA, and protein preparation
Genomic DNA and total RNA were isolated from FF sam-
ples using AllPrep DNA/RNA/Protein Mini Kit (Qiagen)
as per manufacturer’s recommendations. Quantity and
quality of prepared nucleic acids were assessed by spectro-
photometry (NanoDrop Technologies, Inc.). Total protein
from cultured cells was extracted using Laemmli buffer
(BioRad) as cell lysis buffer; protein concentrations were
quantified using Pierce BCA Protein Assay Kit (Thermo-
Fisher Scientific) and GloMax multidetection system (Pro-
mega), as per manufacturer’s instructions.
Gene expression analysis
Total RNA (100 ng) was reverse transcribed using iScript
cDNA synthesis kit (Bio-Rad) as per manufacturer’s in-
structions. Quantitative real-time PCR (qRT-PCR) was per-
formed in triplicate using TaqMan PCR master mix with
FAM fluorophore and probe/primer pairs specific to hu-
man DKK3 (Hs00951307_m1), FOXO1 (Hs01054576_m1),
and RPLP0 (Hs99999902_m1) (ThermoFisher Scientific)
according to manufacturer’s cycling conditions using
CFX96 thermal cyclers (Bio-Rad). Gene expression levels
were normalized to mean RPLP0 expression levels. Relative
gene expression values were calculated using recommended
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Livak method (Bio-Rad). Fold-change expression values
were calculated by base-two logarithmic transformations of
relative gene expression values.
For pathway-focused gene expression analysis, (a) RT2
Profile PCR Array Human WNT Signaling Pathway and
(b) RT2 Profiler PCR Array Human Transcription Factors
were used according to protocol outlined in RT2 Profiler
PCR Array Handbook (Qiagen). Briefly, 100 ng of DNA-
free RNA from each sample was used for 84 target genes
listed in gene lists (available at www.qiagen.com) using
96-well RT2 profiler array format D. cDNA was prepared
using RT2 first strand kit and amplified using RT2 SYBR
Green Mastermix (both from Qiagen) using CFX96 ther-
mal cycler. Differential expression of target genes was cal-
culated using ΔΔCT method on data web portal at
www.SABiosciences.com/pcrarraydataanalysis.php.
Methylation-specific PCR
Methylation status of CpG island A of DKK3 promoter
(Chr11:12029737–12030841) was assessed by MethylScreen
technology using EpiTect Methyl II PCR Assay (Qiagen) as
previously described [30]. Briefly, 125 ng of genomic DNA
was mock-digested or digested with methylation-sensitive
and methylation-dependent restriction enzymes individu-
ally or together, and methylation status of target DNA se-
quence was measured using qRT-PCR with probes specific
to target DKK3 promoter sequence. CT values were con-
verted into percentages of unmethylated, intermediate-
methylated, and hypermethylated CpG values using a quan-
titation algorithm from EpiTect Methyl II PCR Assay
Handbook (Qiagen). Tissue samples were designated as
hypermethylated (>5% alleles with hypermethylation),
intermediate-methylated (>5% alleles with intermediate
methylation), or unmethylated (no methylation detected).
DNA copy number analysis (CNA) by qRT-PCR
DNA from 27 ACC samples that passed specified test
quality criteria were analyzed in quadruplicate with
TaqMan Copy Number Assay using a primer / probe pair
specific to target gene DKK3 or housekeeping gene
RPPH1. Normal adrenal tissue was used for diploid (2n)
reference. Copy numbers were predicted using CopyCaller
software v2.0 (ThermoFisher Scientific). TaqMan Copy
Number Assay used was Hs00228043_cn. Target gene
DKK3 located on Chr.11:11989984 on NCBI build 37.
Housekeeping gene Ribonuclease P RNA Component H1,
RPPH1 located on Chr.14:20811565 on NCBI build 37.
Immunofluorescence (IF) detection of proteins
Five μM-thick FFPE sections were processed for im-
munofluorescence detection of DKK3 and β-catenin
proteins as described previously [31]. Goat anti-DKK3
polyclonal (SC14959; 1:100 dilution) or mouse anti-β ca-
tenin monoclonal (SC47778; 1:200 dilution) primary
antibodies and anti-goat FITC (fluorescein isothiocyan-
ate) and anti-mouse TR (Texas Red) secondary anti-
bodies (1:1000) were used, followed by Ultracruz
mounting agent containing 4′,6-diamidino-2-phenylin-
dole (DAPI) (all from Santa Cruz Biotechnology, Inc.)
for indirect immunodetection. A Zeiss AX10 confocal
microscope with AxioVision 4.8 program was used for
IF analysis, and photomicrographs were taken at a total
magnification of 100× or 400×, as noted.
Cell culture, expression vectors, transfections, and
western blot detection
American Type Culture Collection (ATCC)-authenticated
human ACC cell lines SW-13 (CCL-105) and NCI-H295R
(CRL-2128) were maintained in growth conditions recom-
mended by ATCC, as reported previously [31]. For DKK3
treatments, a working concentration of 5 μg/mL (in PBS)
of human recombinant DKK3 (R&D Systems) was used.
RNAi silencing was carried out with 3 unique 27-mer
siRNA duplexes (designated siA, siB, and siC) targeting
DKK3 (Human) and FOXO1 (Human) transcripts. Univer-
sal scrambled negative control siRNA was used as non-
specific control (all from Origene). Lipofectamine2000-
mediated transfection was carried out in Opti-MEM ac-
cording to manufacturer’s recommendations (Thermo-
Fisher Scientific) in 6-well plates with starting densities of
50,000 cells/well for SW-13 and 80,000 cells/well for NCI-
H295R. Transfection medium was replaced with regular
growth medium after 24 h of transfection. Cells were lysed
for RNA extraction (after 24 h) or protein extraction (after
48 h), and assays were done 48 h post-transfection.
Myc-DDK tagged pCMV6-Entry, pCMV6-Entry/GFP,
and pCMV6-Entry/DKK3 plasmid vectors (Origene) were
used for transient and stable expression. Transient transfec-
tion was carried out in Opti-MEM medium using Lipofec-
tamine2000 according to manufacturer’s recommendations
(ThermoFisher Scientific) in 6-well plates with starting
densities of 50,000 cells/well for SW-13 and 80,000 cells/
well for NCI-H295R cells. Cells were transfected one day
after plating. Transfection medium was replaced with ap-
propriate growth medium 6 h post-transfection, and cells
were assayed for cell behaviors 24 h post-transfection. Total
cell numbers and viability were calculated by staining cells
with 0.4% Trypan Blue (ThermoFisher Scientific) and
counting with hemocytometer (Hausser Scientific Co.). Ex-
periments were performed in triplicate, and parallel
pCMV6-Entry/GFP transfections were used to determine
transfection efficiency.
Stable Geneticin (G418)-resistant pCMV6-Entry,
pCMV6-Entry/GFP, and pCMV6-Entry/DKK3 transfected
clones were selected in 800 μg/mL G418-containing growth
medium (ThermoFisher Scientific). Multiple clones were
then pooled into populations to avoid expression variability
and selection bias between clones. Established populations
Cheng et al. BMC Cancer  (2017) 17:164 Page 3 of 13
designated SW-Neo (from pCMV6-Entry transfections)
and SW-DKK3 (expressing Myc-DDK/DKK3) were com-
pared to parental SW-13 cells to determine effects of con-
stitutive DKK3 expression on SW-13 cells’ malignant
properties. Constitutive DKK3 expression was confirmed
via qRT-PCR using TaqMan primer/probe pairs (Thermo-
Fisher Scientific) and Western blotting using anti-DKK3
mAb (1:500; Abcam), anti-mouse-HRP (Santa Cruz
Biotechnologies, Inc.), Mini-PROTEAN TGX gel, PVDF
blotting membrane (Bio-Rad), and enhanced chemilumin-
escence (ECL) detection reagents (ThermoFisher Scientific)
as per manufacturer’s protocols. Unless specified, 100 μg
protein was loaded per well of 4–10% SDS gels (Bio-Rad).
Equal protein loading was confirmed by staining PVDF
membranes with GelCode Blue Safe Protein stain (Thermo-
Fisher Scientific) after chemiluminescence detection.
Flow cytometric analysis of cell cycle
SW-13, SW-Neo, and SW-DKK3 cells were fixed in cold
70% ethanol for 30 min at 4 °C, washed twice with PBS,
treated with ribonuclease (100 μg/mL), and stained with
propidium iodide (PI; 50 μg/mL in PBS). Using bandpass
filter 605 nm (for PI), forward and side scatter were
measured in a BD LSRII Flowcytometer. Pulse process-
ing was used to exclude cell doublets from the analysis.
FlowJo software was used to analyze the best Gaussian
distribution curve to each peak for the cell populations
of G0-G1 and G2-M.
Cell invasion, migration, adhesion, and clonogenic growth
assays
To assess invasive proficiencies, 100,000 SW-13, SW-Neo,
or SW-DKK3 cells were allowed to invade through Matri-
gel from upper chambers containing serum-free medium
to lower chambers containing 10% FBS medium in BD
BioCoat Matrigel invasion chambers (BD Biosciences).
After 24 h, Matrigel was removed, and invaded cells were
fixed in 3.7% formaldehyde/PBS (10 min), stained with
0.05% crystal violet (30 min), and counted at 100X magni-
fication with light microscope. Matrigel invasion assay
was performed twice in triplicate chambers. In migration
assays, 100,000 cells were allowed to migrate through
8 μM-pore size modified Boyden Chambers (BD Biosci-
ences) from upper chambers containing serum-free
medium to lower chamber with 10% FBS medium. After 4
or 8 h, cells that migrated to lower side of the membrane
were fixed, stained, and counted as above.
Cell adhesion assays were carried out in 6-well plates.
One hundred thousand cells were seeded per well, allowed
to grow overnight, washed with warm PBS, and incubated
with 0.5 mL of 0.25% Trypsin-EDTA for 1 min; Trypsin-
EDTA was then removed, plates were tapped gently to re-
move loosely attached cells, cells were washed with 10%
FBS medium, fixed, stained and counted as above. For
clonogenic growth assays, cells were seeded in 6-well
plates at low densities (5,000 cells/well) and allowed to
grow 7 days in appropriate growth medium (SW-Neo and
SW-DKK3) with medium change every 3 days. On day 7,
cells were washed with PBS, fixed, and stained as above.
Colonies with 12 ± 2 or 4 ± 2 cells were counted as separ-
ate groups and averaged from 6 wells. Experiments were
repeated 3 times, and data from a representative experi-
ment is presented.
Statistical analysis
Normal distribution of continuous variables was assessed
using D’Agostino and Pearson omnibus tests. Normally
distributed variables were analyzed using 2-tailed t test;
Mann–Whitney U test was used for non-normally dis-
tributed variables. For variables with greater than 2
dependent values, a 1-way analysis of variance and
Kruskal-Wallis tests were used for normally and non-
normally distributed populations, respectively. Matched
continuous variables were compared using Pearson cor-
relation. Survival data were assessed by Kaplan-Meier
methods, and differences were compared by Mantel-Cox
test. Statistical analyses were performed using Prism 6
(GraphPad Software).
Results
Reduced expression of DKK3 in adrenocortical carcinoma
Recent comprehensive genetic analyses identified WNT
signaling as the most common target of genetic aberra-
tions in ACCs. To identify novel WNT targets, we com-
pared the expression pattern of selected positive and
negative WNT regulators in 7 ACC samples using an ex-
panded WNT expression array. Among various differen-
tially expressed WNT regulators, the expression of DKK3,
a negative WNT regulator and a putative tumor suppres-
sor in a wide variety of tumors, was found significantly re-
duced in the majority (6/7) of the ACC samples tested
(Fig. 1a; Additional file 1: Figure S1). Further, compared to
the robust expression pattern in adrenal cortex, DKK3
protein expression was found to be nearly absent in ACCs
by indirect immunofluorescence analysis (Fig. 1b; a&h).
DKK3 was observed to be expressed in the zona fascicu-
lata and zona reticularis (data not shown) in normal ad-
renal cortex, though to a lesser extent going inward from
the zona glomerulosa (Fig. 1b). In contrast to the near ab-
sence of DKK3, β-catenin appeared to be over-expressed
in ACC (Fig. 1b; h). Moreover, both robustly expressed
DKK3 and weakly expressed β-catenin proteins were
found predominantly in the cytoplasmic compartment of
normal adrenal cortex (Fig. 1b; b-g), while increased β-
catenin levels were found both in the cytoplasm and the
nuclei of ACC cells (Fig. 1b; i-n). Due to the rarity of the
disease and scarcity of fresh-frozen samples, an inter-
national patient cohort (n = 38) was assembled for DKK3
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expression analysis (Table 1). Quantitative RT-PCR ana-
lysis of 37 ACC samples confirmed reduced mRNA ex-
pression in the majority (70%; 26/37) of ACC samples
(Fig. 1c). The mean expression of DKK3 in 37 ACCs was
significantly decreased (p = 0.002) compared to mean
DKK3 expression in 14 normal adrenal tissue samples
(Fig. 1d). The high frequency of DKK3 silencing (70%)
observed in ACCs is very similar to that observed in other
malignancies including thyroid [32] and pancreatic
cancers [33].
To determine whether reduced DKK3 expression corre-
lated with disease presentation and/or outcome, we ana-
lyzed statistical correlation to various patient characteristics
(Table 1), including age, gender, tumor size, tumor weight,
ENSAT stage, and hormone secretion phenotypes. Despite
the limited cohort size (n = 38), reduced DKK3 expression
showed a non-significant trend (p = 0.062) towards female
gender (Additional file 1: Figure S2). Kaplan-Meier survival
analysis also did not reveal a significant effect on survival in
patients with reduced DKK3 expression (p = 0.19)
(Additional file 1: Figure S3).
DKK3 promoter methylation and gene copy number
alterations in ACC
Promoter methylation has been identified as the principal
mechanism of DKK3 silencing in multiple tumor types
[34–39]. Moreover, we have previously shown potential
involvement of global and gene-specific promoter methy-
lation changes in ACCs [40]. Using the EpiTect protocol
[31], we analyzed methylation status of the DKK3 pro-
moter in 9 normal adrenal tissue and 29 ACC samples.
Compared to the DKK3 promoter methylation status in
normal adrenal DNA, 4 ACC samples (14%) showed
marked levels of hypermethylation, and 14 samples (48%)
showed intermediate-range methylation (Table 2). Twelve
of 18 ACC samples with hyper- or intermediate promoter
methylation (67%) also showed significant reduction in
DKK3 expression, concurring with the established role of
Fig. 1 Reduced DKK3 expression in ACC. a Reduced DKK3 gene expression in 7 tumor samples (T1–T7) compared to 3 histologically normal adrenal
samples (N1–N3). T5a and T5b: RNA from two different areas of one tumor. Magnitude of gene expression relative to housekeeping gene panel shown
below. b Immunofluorescence detection of DKK3 and β-catenin in normal adrenal cortex (a-g) and ACC (h-n). Tissue sections treated with
primary/secondary antibodies for DKK3 (FITC, green; c, j) or β-catenin (TR, red; e, l), DAPI (blue for nuclear staining; b, i), or combinations of
FITC/DAPI (d, k), TR/DAPI (f, m), or FITC/TR/DAPI (a, h, g, n). a and h: 100× magnification; b-g, i-n: 400× magnification; inset (g, n): 1000×
magnification. c DKK3 gene expression (fold-change) in 37 ACC samples relative to average expression of 14 normal adrenal samples
normalized to 1. d Average DKK3 expression (fold-change) in study cohort (n = 37) compared to average expression from 14 normal
adrenal samples
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promoter methylation in DKK3 silencing in other tumors
[36, 37]. Interestingly, 8/11 samples with non-methylated
promoters also showed comparable frequency of DKK3 si-
lencing (72%), suggesting alternate mechanisms for DKK3
down-regulation in ACC.
Recent genetic analyses of ACCs by us and others have
shown significant copy number alterations in genes po-
tentially involved in various signaling pathways [30]. To
determine if gene copy loss contributed to reduced ex-
pression of DKK3 in this cohort of ACC samples, we
analyzed copy number variations using the TaqMan copy
number assay. We found copy losses in 9 samples (33%)
and copy gains in 3 of 27 ACC samples tested (Table 2;
Table 1 Summary of cohort demographics and patient
characteristics
Characteristics Number of Cases Percentage
























No information available 4 10.5%
Outcome
Alive, no recurrence 11 28.9%
Alive, recurrence 5 13.2%
Death from disease 16 42.1%
Death from other causes 4 10.5%
Lost to follow-up 2 5.3%
aTumors secreting two or more of the following hormones: aldosterone,
cortisol, testosterone, or DHEA
y years, cm centimeter, SD standard deviation, ENSAT European Network for
the Study of Adrenal Tumors, DHEA dehydroepiandrosterone, NA
not applicable
Table 2 DKK3 mRNA expression, promoter methylation, and
gene copy number alterations in adrenocortical carcinoma
Sample Gene Expression Promoter Methylation Gene Copy Number
1 L IM 2
3 L HM 2
5 L HM 2
7 L UM 1
11 L UM 1
13 L UM 2
15 L UM ND
17 L UM 1
19 L HM 1
21 L IM 2
25 L IM 2
29 L IM 1
31 L IM 2
35 L ND ND
37 L ND ND
39 L ND ND
41 L IM 2
43 L ND ND
45 L UM ND
47 L IM 1
53 L IM 1
57 L HM 6
63 L UM 2
65 L UM 3
75 L ND ND
77 L ND ND
9 ND IM 2
23 N UM 2
33 N IM 2
49 N IM 2
71 N ND ND
27 H IM 1
51 H IM 3
55 H IM 1
59 H UM 2
61 H UM 2
69 H ND ND
73 H ND ND
Abbreviations: DKK3 Dickkopf-related protein 3, L low expression, N normal
expression, H high expression, UM unmethylated, IM intermediate methylation,
HM hypermethylation, ND not determined
Cheng et al. BMC Cancer  (2017) 17:164 Page 6 of 13
Additional file 1: Figure S4). Seven of the 9 samples with
copy loss (78%) showed marked reduction in DKK3 ex-
pression; 4 showed concurrent DKK3 promoter methyla-
tion. Interestingly, one ACC sample (ID #57) with 6
copies of the DKK3 gene also showed promoter hyper-
methylation and reduced expression of DKK3.
DKK3 silencing reduces clonogenic growth and promotes
migration of ACC cells
To test whether DKK3 plays a tumor suppressor role in
ACC in vitro, we investigated the expression pattern and
regulation of DKK3 in two ACC cell lines, SW-13 and NCI-
H295R. Western blot analysis showed modest expression of
DKK3 in SW13 cells, while NCI-H295R cells showed low
expression (Fig. 2a). Despite carrying TP53 gene mutations,
non-hormone-secreting SW-13 cells maintain an
unperturbed and modifiable WNT signaling pathway,
whereas the adrenal hormone-producing NCI-H295R cells
harbor CTNNB1 and axin1 mutations, resulting in consti-
tutive WNTactivation [31, 41]. To test whether suppressing
endogenous DKK3 will influence malignant properties of
ACC cells, we used a transient siRNA-silencing method. Si-
lencing of DKK3 expression in SW-13 (Fig. 2b, d) and NCI-
H295R (Fig. 2c) cells with siRNA was confirmed by qRT-
PCR (Fig. 2b-c) and Western blot (Fig. 2d). DKK3 silencing
did not result in significant loss of viability in either cell type
for the duration of study (48 h). Due to low baseline levels
of DKK3 in H295R (Fig. 2a), siRNA-mediated silencing has
no detectable effect observable by Western (data not
shown). Next, we examined whether silencing of DKK3
modulates clonal growth or migratory potential of ACC
cells. Partial silencing (40% suppression; Fig. 2c) of DKK3
Fig. 2 RNAi silencing of DKK3 in ACC cell lines and effects on cell behavior. a Western immunoblot detection of endogenous DKK3 in SW-13 (left) and
NCI-H295R (right). b and c, Relative expression of DKK3 as determined by qRT-PCR in siRNA-treated SW-13 (2B) and NCI-H295R (2C) cells, normalized to
expression in cells treated with scrambled siRNA for 24 h. dWestern immunoblot detection of DKK3 in SW-13 cells treated with control (1), scrambled
negative siRNA (2), 10 (3), 20 (4), and 40 nM (5) DKK3 siRNAs for 24 h followed by protein extraction 48 h post-transfection. e-h, NCI-H295R (e and f) or
SW-13 (g and h) cells treated with Lipofectamine (Lipo), scrambled negative siRNA (S-ive), or DKK3 siRNA (DKK3) for 24 h, allowed to grow in clonogenic
growth conditions (e and g), or allowed to migrate through modified Boyden chambers through growth factor concentration gradient for 12 (f) or 4 (h)
hours. Clones with 12 ± 2 cells were fixed, stained, and counted with light microscope (e and g); cells that migrated to lower side of modified Boyden
chamber membranes were fixed, stained, and counted (f and h)
Cheng et al. BMC Cancer  (2017) 17:164 Page 7 of 13
(Fig. 2a) did not appear to influence clonogenic growth or
migratory potentials of NCI-H295R cells (Fig. 2e-f). It is
conceivable that the constitutively active WNT signaling in
these cells may have conferred inherent resistance to DKK3
signaling. On the other hand, DKK3 silencing in SW-13
cells (75% suppression; Fig. 2b; lane 5 of Fig. 2d) signifi-
cantly impaired the cells’ ability to form colonies in isolation
(p = 0.001) (Fig. 2g) and promoted their motility behavior
(p = 0.001) (Fig. 2h; Additional file 1: Figure S7). These re-
sults suggest a potential role for DKK3 silencing in adrenal
carcinogenesis, which could be overrun by gain-of-function
WNT mutations.
Exogenous DKK3 promotes migration of SW-13 cells
Reports suggesting distinct roles for endogenous and se-
creted DKK3s in cell behavior [17, 42] prompted us to test
the effect of exogenous DKK3 addition to ACC cells. Cells
grown in the presence of exogenous human recombinant
DKK3 did not show a difference in their overall growth
potentials (Additional file 1: Figure S5). However, migra-
tory potential of SW-13 cells was found to be accentuated
with exogenous DKK3 (Fig. 3a). The exogenous DKK3 in
this instance appears to have a dominant effect over the
motility-impeding effect of endogenous DKK3 (Fig. 3a &
f). NCI-H295R cells with constitutively active β-catenin
appeared to be resistant (Fig. 3a) to the exogenous DKK3-
induced migration-promoting effects on SW-13 cells.
Constitutive over-expression of DKK3 stifles malignant
behavior of ACC cells
DKK3 is constitutively expressed and persistently present
during zonal differentiation of adrenal cortex [14]. To test
whether constitutive over-expression of DKK3 promotes
redifferentiation of ACC cells, we generated a stable popu-
lation of SW-13 cells engineered to over-express DKK3.
Since NCI-H295R cells exhibited no appreciable response
to either endogenous or exogenous DKK3 (Figs. 2e-f and
3a), we limited our attention to SW-13 cells. Expression of
ectopic DKK3 was confirmed (Fig. 3b), and SW-DKK3
cells were assessed for various malignant properties com-
pared to parental SW-13 and control SW-Neo cells.
SW-DKK3 cells grew at a slower rate compared to both
parental SW-13 and SW-Neo cells (Fig. 3c). The slow rate
of growth of SW-DKK3 cells was found to be caused by
an increase in the percentage of cells accumulated in G1
phase (47.5% SW-Neo compared to 56.3% SW-DKK3
cells) of the cell cycle (Additional file 1: Figure S6). Since
suppression of endogenous DKK3 expression resulted in
reduced clonogenic growth and increased motility of SW-
13 cells, we compared clonal growth and migratory poten-
tial of SW-DKK3 cells to that of SW-Neo cells, using
parental SW-13 cells as reference. Compared to their
vector-transfected controls, SW-DKK3 cells showed an
overall increase in clonal growth efficiency (Fig. 3d).
Interestingly, 52% of the clones were small (4 ± 2 cells)
and composed of larger, slow-growing, or growth-arrested
cells (Fig. 3e; right). In SW-Neo, this fraction of small
clones represented only 9% of the clones (p < 0.001), while
the remaining 91% constituted large colonies comprised
of 12 ± 2 cells (Fig. 3e; left).
Next, we assessed the effect of constitutive DKK3
over-expression on migratory potential of SW-13 cells.
SW-DKK3 cells exhibited significantly decreased migra-
tory potential compared to parental SW13 and SW-Neo
cells (p < 0.001) (Fig. 3f ). To test whether DKK3-
promoted reduction in SW-13 cells’ migratory potential
has a potential in vivo implication, we performed an in
vitro invasion assay. As reported previously in other can-
cer types [26], over-expression of DKK3 significantly im-
paired SW-13 cells’ ability to invade through
reconstituted matrix (p < 0.001) (Fig. 3g).
DKK3 promotes a more differentiated phenotype in ACC
cells
To test whether decreased invasive behavior of DKK3-
over-expressing SW-DKK3 cells is due to signaling
changes that can potentially modulate cell spreading and
thereby migration kinetics, cell morphology was ob-
served under light microscopy. SW-DKK3 cells appeared
to be larger with an extensive spreading phenotype aided
by dysregulated cell edge attachments (Fig. 4a-c). While
the parental SW-13 and SW-Neo cells displayed a sig-
nificantly higher number of filopodia in a planar orienta-
tion, SW-DKK3 cells displayed a significantly higher
proportion of lobopodial extensions (p < 0.01) (Fig. 4a-
d). To test whether the differential expression of cell
extensions alters cell attachment characteristics, we per-
formed a cell-detachment assay. SW-DKK3 cells showed
a significantly stronger attachment to substratum com-
pared to both SW-13 and SW-Neo cells (p < 0.01)
(Fig. 4e). Whether increased attachment strength to sub-
stratum or multidirectional polarity conferred by the
multitude of lobopodial attachments acts independently
or in tandem towards reduced invasive behavior of SW-
DKK3 cells needs to be studied further.
FOXO1 as a potential DKK3 target to effect
redifferentiation
Towards understanding the potential transcriptional modu-
lation of cell adhesion and motility by DKK3 over-
expression, we compared global difference in the expression
pattern of 84 transcription factors using an expanded tran-
scription array. Relative expression of 3 transcription
factors, ID1, JUN, and FOXO1, consistently demonstrated
>4-fold difference in expression between SW-DKK3 and
SW-Neo/SW-13 cells (Additional file 1: Figure S8 A&B).
Transcription factors ID1 and JUN have been shown to me-
diate a variety of phenotypic effects, including apoptosis via
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DKK3 signaling, in multiple cancers (44, 45). DKK3-stifled
invasive behavior independent of loss of viability observed
in SW-13 cells prompted us to investigate a potentially
novel role for FOXO1 transcription factor in DKK3-
promoted redifferentiation of ACCs. Increased expression
of FOXO1 in SW-DKK3 cells was confirmed by qRT-PCR
(Additional file 1: Figure S8C). Using siRNA, we transiently
silenced FOXO1 expression in SW-DKK3 and control SW-
Neo cells (Additional file 1: Figure S9A&B) and assessed
the effect of silencing on cell motility. Irrespective of DKK3
expression (Fig. 3b), both cell types showed an increase in
migratory potential upon FOXO1 silencing (Fig. 5). The
magnitude of relief in migratory inhibition was found to be
more pronounced in SW-DKK3 cells (45% increase in mo-
tility with 43% FOXO1 suppression) than in SW-Neo cells
(30% increase in motility with 66% FOXO1 suppression;
Additional file 1: Figure S10). These results clearly suggest
a role for FOXO1 in mediating DKK3-promoted redifferen-
tiation and/or anti-invasive signaling in SW-13 ACC cells.
Discussion
DKK3 expression is down-regulated in many human
cancers, including that of the thyroid, lung, prostate,
colon, breast, and liver [32, 33, 36, 43], but its
Fig. 3 ACC cells were either treated with exogenous recombinant DKK3 (a) or enforced to express Myc-DDK tagged DKK3 (b) and assayed for cell
behaviors. a SW-13 N/D (left) or NCI-H295R (right) cells were untreated (SW N/D-, 295-) or treated (SW N/D+, 295+) with exogenous DKK3 for 24 h and
allowed to migrate through modified Boyden chamber for 4 h. Cells migrating to lower surface were fixed, stained, and counted. b Western immunoblot
detection of endogenous DKK3 and ectopically expressed DKK3 (Myc-DDK/DKK3) in vector control (lane 1), SW-DKK3 (lane 2), or Myc-DDK/GFP control (lane
3) cells. c SW-13, SW-Neo, and SW-DKK3 cells plated in 24-well plates (5000 cells/well) were grown 8 days. Quadruplicate wells from each
cell type were trypsinized, incubated in 0.2% Trypan blue, and viable cells were counted using hemocytometer. Data shown represent
one of three independent experiments. d and e, Five thousand SW-13 or SW-DKK3 cells plated in 6-well plates were allowed to grow
7 days; clones were fixed, stained, and enumerated into 2 classes of (a) 12 ± 2 cells (filled light grey) and (b) 4 ± 2 cells (filled black). Majority of
clones formed from SW-Neo cells were large (e; left), while SW-DKK3 cells produced a significant number of small colonies (4 ± 2) comprised of large
cells (e; right). f One hundred thousand SW-13, SW-Neo, and SW-DKK3 cells were allowed to migrate through modified Boyden chamber for 4 h; cells
that migrated to the lower side of the membrane were fixed, stained, and counted. g One hundred thousand SW-13, SW-Neo, and SW-DKK3 cells were
allowed to invade through Matrigel in modified Boyden chambers for 24 h. Cells that invaded through Matrigel and migrated to the lower side of the
membrane were fixed, stained, and counted
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regulation in ACC is unclear. In this study, we uti-
lized comprehensive genetic, epigenetic, and func-
tional approaches to identify and characterize a
potential tumor suppressor role for DKK3 in adrenal
carcinogenesis. Our study showed a significant de-
crease in DKK3 expression in 70% (25/37) of ACCs,
strongly suggesting a tumor suppressor role for DKK3
in human adrenal tissue. Whether the observed silen-
cing in malignant samples represents an earlier dedif-
ferentiation or a later malignancy-promoting event
needs to be determined. Despite the relatively small
cohort size, this study did not find an association be-
tween DKK3 silencing and prognosis, unlike in gastric
cancer [35]. Of note, the majority of this cohort of
ACCs was previously shown not to harbor mutations
in DKK3 or FOXO1 genes while <10% carried beta-
catenin mutations [24].
Epigenetic modifications, including promoter methyla-
tion and chromatin condensation, have been proposed
as major DKK3 silencing mechanisms in a variety of tu-
mors [43]. This study also supports a role for promoter
hypermethylation in DKK3 silencing in ACCs. Interest-
ingly, DKK3 expression was also significantly decreased
in many samples with intermediate methylation (48%),
suggesting that even intermediate levels of methylation
may be adequate to silence DKK3 expression. Whether
the DKK3 promoter methylation observed in this study
is a component of the global methylation changes ob-
served in ACCs [9, 40] or a specific DKK3 gene-targeted
event needs to be clarified. A large proportion of the
ACC study cohort with non-methylated promoters but
with reduced DKK3 expression led us to seek alternate
mechanisms for DKK3 down-regulation in ACC. In light
of recent findings that gene copy number variations may
Fig. 4 Constitutive over-expression of DKK3 reorganizes cellular extensions and cell spreading. a-c SW-13 (a), SW-Neo (b), and SW-DKK3 (c) cells were
grown on glass cover-slips, fixed, stained, and photographed. SW-13 and SW-Neo cells show a predominance of filopodia (red arrowheads) around edges;
SW-DKK3 shows more lobopodia (small green arcs), absence of lamellipodia (blue arc), and few filopodia around edges. While cells in a and b appear to be
polarized with filopodia at leading edge and lamellipodia at lagging edge, SW-DKK3 cells (c) show evenly spread flat lobopodia with extensive spreading
and absence of polarity. Photomicrographs are taken using light microscope at 400× magnification. d Average number of lamellipodia, filopodia, and
lobopodia per cell calculated from manual counting of cell extensions. Twenty randomly taken (400× magnification) photomicrographs of SW-13, SW-Neo,
and SW-DKK cells used for quantification. e One hundred thousand SW-13, SW-Neo, and SW-DKK3 cells/well of 6-well plates were allowed to grow
overnight, detached at specified times, cells remaining attached were fixed, stained, and counted manually
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contribute to adrenocortical carcinogenesis [8, 24], we
analyzed a portion of our samples for DKK3 gene copy
number variations. The majority of samples identified
with DKK3 copy loss also had significantly reduced
DKK3 expression. Only a handful of these samples had
concurrent promoter methylation, indicating a possible
independent role for gene copy loss in causing DKK3
down-regulation in ACC. One ACC sample with 6 cop-
ies of DKK3 and a hypermethylated promoter had sig-
nificantly reduced expression of DKK3, suggesting that
copy number variations may occur earlier in ACC onco-
genesis than gene-specific methylation events.
Statistical correlation to patient characteristics and out-
comes did not reveal any prognostic association of reduced
DKK3 expression in ACC patients, although reduced
DKK3 expression was found to trend non-significantly to-
ward female gender. This study did not reveal a relationship
between DKK3 expression and aldosterone biosynthesis, as
reported earlier [25]. In addition, no significant correlation
was observed in our tumor cohort between DKK3 expres-
sion, metastasis, and tumor grade.
We used functional approaches to characterize the ef-
fects of DKK3 on human ACC cells. Silencing of DKK3
in SW13, a human ACC cell line with intact and induc-
tile WNT signaling and endogenously expresses DKK3,
did not affect growth or viability of cells but resulted in
reduced clonogenic growth and increased motility, con-
sistent with a tumor suppressor role for DKK3 [31, 41].
In contrast, exogenous addition of DKK3 to SW-13 cells
resulted in increased motility, suggesting distinct roles
for intracellular and secreted DKK3s. This observation is
consistent with recent suggestions that DKK3 potentially
has distinct intracellular signaling partners independent
of canonical WNT-β-catenin circuitry [26]. Overall,
intracellular DKK3 appears to confer a more differenti-
ated phenotype to SW-13 cells. Whether the observed
DKK3-promoted more differentiated phenotype is
through (a) reactivation of the proposed adrenocortical
differentiation pathway [14], (b) blocking of malignancy
signaling networks, or (c) activation of a novel rediffer-
entiation pathway needs to be clarified.
Light microscopic analysis revealed drastic changes in
organization of cell outgrowths on the edges of slow-
moving SW-DKK3 cells. While parental SW-13 and SW-
Neo cells produced an overwhelming number of dynamic
filopodia that confer polarity and promote directional
movement (41–43), SW-DKK3 cells showed predomin-
antly lobopodia, indicative of multipolar spreading and
hence arrested motility [44–46]. Although DKK3 has pre-
viously been shown to influence migratory and invasive
phenotypes in multiple cancer cell types, an association of
cell surface modifications that can impact cell mobility
has not been shown. The mechanism(s) that elicit the ob-
served changes in cell extension repertoire need to be in-
vestigated further. The association of the dedifferentiated
phenotype and loss of DKK3 expression in ACC, com-
bined with the re-acquisition of a relatively more differen-
tiated phenotype in SW-13 ACC cells overexpressing
DKK3, suggest a global differentiation role for DKK3 in
adrenal cortex and the possibility that DKK3 could serve
as a re-differentiation therapeutic target.
To explore potential pathways involved in eliciting the
observed DKK3-promoted redifferentiated phenotype of
ACC cells, we compared the expression pattern of 84 hu-
man transcription factors. Of the 3 transcription factors
found to be over-expressed in SW-DKK3 cells (ID1, JUN
and FOXO1), FOXO1 secured our immediate attention for
3 primary reasons: (1) FOXO1 is known to promote func-
tional differentiation of myofibroblasts [47], (2) FOXO1 in-
hibits osteosarcoma malignancy via WNT inhibition [48],
and (3) FOXO1 transcription has been suggested in re-
sponse to steroid hormones [49]. We hypothesized that
intracellular DKK3 promotes cellular differentiation signal-
ing encompassing cellular spreading and stifled motility, at
least in part, via FOXO1 up-regulation. FOXO1 RNAi silen-
cing resulted in partial reversal of the motility suppression,
suggesting that FOXO1 may indeed play a role in DKK3-
promoted redifferentiation of ACC cells. Based on the in-
verse relationship observed in ACC tissue between DKK3
Fig. 5 FOXO1 silencing releases DKK3-mediated block of cell migration.
Cells were treated with scrambled negative siRNA (Neg.) or FOXO1 siRNA
(Si-RNA) for 24 h, trypsinized, and allowed to migrate for 4 h through
modified Boyden chamber. Migrated cells were fixed, stained, and
counted manually. Total number of SW-Neo cells treated with scrambled
siRNA normalized to 100%, and relative change in migration of SW-Neo
and SW-DKK3 cells treated with FOXO1 siRNA is shown in overlapping
line graph on left Y-axis. Relative FOXO1 expression in SW-Neo and
SW-DKK3 cells treated with FOXO1 siRNA, normalized to FOXO1
expression in SW-Neo cells treated with scrambled siRNA set at 100
shown as bars on right Y-axis
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and beta-catenin expression, it can be assumed that DKK3/
FOXO1 regulation of malignant behavior of SW-13 cells is
mediated through beta-catenin signaling. However, the pre-
cise DKK3-FOXO1 signaling circuitry in the context of ad-
renocortical differentiation needs to be investigated further.
Conclusions
In conclusion, we demonstrate for the first time that
DKK3 expression is frequently reduced in ACC, poten-
tially contributing to adrenal dedifferentiation and/or pro-
gression of malignancy. Further, we identified FOXO1 as a
downstream effector of DKK3 that may play a role in
blocking adrenocortical dedifferentiation. These results
suggest a potential for developing novel redifferentiation-
focused pharmaceuticals that could allow successful
treatment of ACCs when used in concert with existing
treatment regimens.
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